Company ProfilePremium

AVT Natural Products Limited

Company Profile Analysis

Tickers: AVTNPL.NS, 519105.BO

ESOMAR 23 Corporate BadgeISO Certifications Badge
AVT Natural Products Limited - Company showcase

Year Founded & Workforce

1986

320 Employees

AVT Natural Products Limited logo

AVT Natural Products Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

AVT Natural Products Limited Overview

AVT Natural Products is a small-cap, export-oriented Indian maker of plant-derived ingredients, and part of the Chennai-based A.V. Thomas Group. Its main businesses are:

  • Marigold extracts (lutein and xanthophylls) for eye-health nutraceuticals, food colour and poultry pigmentation

  • Spice oils and oleoresins (paprika, capsicum, pepper and others)

  • Value-added teas (decaffeinated and instant/soluble)

  • A smaller but fast-growing line of botanical animal health and nutrition products

The model is backward-integrated in marigold. The company contracts tens of thousands of farmers, supplies seed and agronomy support, and processes the flowers in plants in Kerala and Karnataka.

About 93% of standalone sales are exports. The US accounted for roughly 45% of FY2025 sales, and the top five customers for over 80% of revenue. Customers include Kemin Industries, which buys marigold oleoresin under a long-term exclusive supply agreement.

AVT combines a net-cash, A+-rated balance sheet with heavy working-capital intensity. After a weak FY2024–FY2025, earnings re-accelerated sharply in FY2026 and Q1 FY2027.


What the company does — company description

The company describes itself in its exchange profile and annual report as a manufacturer of plant-based extracts and natural ingredient solutions. It serves the food, beverage, animal nutrition and nutraceutical industries worldwide.

Exchange-filed descriptions list five primary business categories:

  1. Marigold extracts for eye care, food colouring and poultry pigmentation

  2. Spice oleoresins and oils for food colouring and flavouring

  3. Value-added teas: decaffeinated teas and instant teas

  4. Animal health and nutrition products

  5. Agricultural crop inputs

Single reporting segment. For Ind AS 108 purposes the company reports one segment. The FY2026 NSE filing labels this segment "Solvent Extraction"; earlier annual reports call it "Food & Feed Ingredients from Natural Raw materials". Its business operations are described as being mainly in India, the USA, the UK and the UAE.

Independent characterisation

End-marketAVT products usedDemand driver
Human nutraceuticalsLutein/zeaxanthin from marigoldEye health and ageing populations
Food and beverage colour and flavourPaprika and capsicum oleoresins, marigold colour, spice oilsClean-label replacement of synthetic dyes
BeveragesInstant tea for RTD/iced tea and premixes; decaffeinated teaConsumer tea consumption formats
Animal nutritionPoultry pigmentation (xanthophylls); botanical feed additivesAntibiotic-free production trends
Crop inputsNot detailedSmall category
Personal care and cosmeticsFunctional botanicals (antioxidant, UV-protection, melanin-inhibition, plant-based collagen-replacement actives, per the company's marketing descriptions)Natural actives; scale not disclosed

AVT is best understood as a contract-oriented B2B botanical extraction house. It is not a consumer brand. Its economics rest on four things:

(a) Raw-material access.

  • Marigold is the anchor crop. A 2020 company release cited about 35,000 acres under cultivation, about 100,000 metric tonnes of flowers a year and a network of about 30,000 farmers.

  • Spices and tea are bought largely at market prices.

(b) Extraction and refining capability.

  • The core process is solvent extraction followed by refining, concentration, decaffeination and spray/freeze-drying for soluble tea.

(c) Embedded positions with a handful of global ingredient majors.

  • Long-term relationships with large customers drive repeat orders.

  • The exclusive marigold-oleoresin supply agreement with Kemin Industries (US) is the most important of these.

(d) Export pricing.

  • Revenue is earned predominantly in USD, EUR and GBP.

  • Costs are largely in INR, so currency movements feed directly into margins.

Revenue model. The revenue model is almost entirely product sales: bulk ingredients sold under supply agreements and purchase orders.

  • No subscription or licensing revenue is disclosed.

  • Some marigold supply is order-backed, meaning procurement is matched to customer orders. ICRA notes this limits inventory price risk.

  • Tolling or processing-service revenue, if any, is not separately disclosed.

Value chain position. AVT sits upstream-to-midstream:

  • It performs seed selection, breeding and contract cultivation for marigold.

  • It then extracts and refines the raw material into oleoresins, crude lutein esters and concentrated tea solubles.

  • Most output goes to formulators who make finished branded ingredients. For example, Kemin converts marigold extracts into branded lutein products for supplements and feed.

  • AVT therefore captures less of the end-value than branded ingredient companies, but carries agricultural and working-capital risk.

Customer types.

  • Global specialty ingredient companies

  • Flavour and colour houses

  • Beverage and tea companies (instant tea and decaffeinated tea buyers in the US, UK and Europe)

  • Animal-nutrition integrators and feed-additive distributors (US, Latin America, Middle East)

End-markets served.

Revenue mix by product category (indicative)

Category (FY2025, % of revenue, ICRA indicative)FY2025
Marigold extracts (% of revenue, "less than")40
Spice oils and oleoresins (% of revenue, "around")25
Beverages — instant and decaf tea (% of revenue, "around")30
Animal nutrition and others (% of revenue, residual, approximate)5

The company does not report product-category revenue in its segment note. The best public indication is ICRA's December 2025 rationale for FY2025:

  • Animal nutrition revenue grew more than 60% year on year in FY2025, from a small base (ICRA).

  • Marigold's share has fallen sharply over time. It was about 60% in FY2014 and about 40% in FY2020 (Outlook Business, citing company data).

Strategy

Stated strategic themes (annual-report MD&A, paraphrased)

  1. Marigold remains the core. It is to stay a key segment for both revenue and profit, with the emphasis on sustaining growth through efficiency because of low marigold prices and renewed Chinese competition.

  2. Value-added tea as the major growth engine. The aim is to consolidate the company's position as a key player in value-added tea. New soluble-tea offerings are being launched for instant-tea customers.

  3. Specialty focus in spice oleoresins to protect margins rather than chase volume.

  4. New segments. Animal health and nutrition, functional ingredients with cross-division applications, and new complementary product lines with nutritional applications.

  5. Procurement discipline. Strategic buying and diversification of suppliers to stay cost-competitive. Farmer engagement (seeds, training) to secure marigold acreage against competing high-value crops.

Initiatives in the last 24 months

InitiativeDateDetailStatus
Professional CEO appointmentSep 2025 (confirmed for five years May 2026)K. Nandakumar recruited from outside the industry. His track record is in industrial and consumer multinationals, with an emphasis on P&L, cash flow and new business modelsIn progress
Board refreshJun 2024 – Jun 2026New independent directors replacing those completing tenure; next-generation promoter family (Rahul Thomas, Siddharth Thomas) inductedCompleted
Working-capital limit enhancementDec 2025Rated cash-credit limit raised from ₹74.5 crore to ₹95 crore; non-fund-based limits to ₹15.33 croreCompleted
Capex programmeFY2026–FY2027₹15–20 crore a year, internally funded (ICRA)FY2026 capex about ₹23 crore
Animal nutrition geographic build-outOngoingUS, Mexico and UAE subsidiaries; segment grew more than 60% in FY2025Ongoing

Cost programmes with quantified targets: none disclosed.

Medium-term financial targets / guidance: none publicly disclosed. The company does not hold earnings calls or publish investor presentations, based on the sources reviewed.

Products & Services

The company does not publish SKU-level pricing. Launch years for individual products are generally not disclosed. Brand names other than "Optim Health" are not disclosed in the sources reviewed.

Marigold extracts (about <40% of FY2025 revenue)

ProductDescription and specificationsTarget customerNotes
Food- and nutraceutical-grade marigold oleoresin / lutein estersSolvent-extracted oleoresin from Tagetes erecta petals; source of lutein and zeaxanthin for eye-health supplementsGlobal nutraceutical ingredient majors, chiefly Kemin Industries under an exclusive long-term agreementAVT describes itself as a leader in food-grade marigold oleoresin. Chinese producers compete aggressively on price
Marigold colour for foodNatural yellow-orange colourantFood colour houses and food manufacturersClean-label colour replacement
Feed-grade marigold extract / xanthophyllsPoultry pigmentation (egg-yolk and broiler-skin colour)Feed premix and additive companiesThe company's original product line
Seed and cultivation programmeSeed selection, breeding and cultivation for proprietary marigold lines; farmer trainingInternal (backward integration)About 30,000 farmers and 35,000 acres (2020 data)

Spice oils and oleoresins (about 25% of FY2025 revenue)

ProductDescriptionTarget customer
Paprika oleoresinNatural red colour, standardised colour valueFood colour, meat and snacks seasoning
Capsicum oleoresinPungency (capsaicin) standardised extractSeasoning and food manufacturers
Black pepper oleoresin and oilFlavour (piperine), aromaFlavour houses, seasoning blenders
Rosemary extractNatural antioxidant (carnosic acid) for shelf-life extensionFood, feed and oils manufacturers
Other spice extracts"New spice extract offerings" are referenced in management discussion; specific spices not disclosedFlavour and colour houses

Management's stated focus in spice oleoresins is on specialty products to protect margins, rather than commodity volume.

Value-added teas — beverages (about 30% of FY2025 revenue)

ProductDescriptionTarget customer
Instant / soluble tea (black and green)Concentrated tea solids for RTD iced tea, premixes and vending; hot and cold blendsUS, UK and European beverage brands and blenders
Decaffeinated teaDecaffeination of black and green teas for bag and loose-leaf brandsUK/EU tea brands, via AVT Natural Europe
New soluble tea offeringsNew grades launched for instant-tea customers (per MD&A); details not disclosedExisting instant-tea customers
Tea infusions and natural flavouring blendsReferenced as growth drivers in MD&APremium-segment brands
  • Management has repeatedly described value-added tea as a major growth area.

  • An earlier volume target was 1,000 MT of tea for FY2021.

Animal health and nutrition (small; grew more than 60% in FY2025)

ProductDescriptionTarget customer
Botanical feed additivesPlant-based solutions for animal health and performance. Product names not disclosed in sources reviewedPoultry, swine and cattle integrators in North America, Latin America and the Middle East
Poultry pigmentation (crosses over with marigold)Xanthophyll-based pigmentersFeed mills

The animal-nutrition line is marketed through AVT Natural North America Inc. (US), AVT Natural S.A. de C.V. (Mexico) and AVT Natural FZCO (UAE).

Other categories

ProductDescriptionStatus
Agricultural crop inputsListed as a business category in exchange profilesScale not disclosed
Functional botanicals and clean-label ingredientsFunctional fibres, vegetable proteins; antioxidant, anti-inflammatory, melanin-inhibition, UV-protection and plant-collagen-replacement actives; natural coloursMarketed on the website; revenue not disclosed
Optim Health (domestic consumer supplements)Launched Dec 2013Limited traction; small number of products available (Outlook Business)
De-oiled cake (legacy)Soybean/oilseed meal, historical capacity 56,500 tpaHistorical.

Financial Detail

Results by Segment and Segment Margins & Growth (%)

MetricFY2024FY2025FY2026

Segment revenue — single segment (INR Cr, consolidated)

517559713

Segment EBITDA (INR Cr, consolidated operating profit)

797390

Segment EBITDA margin (%)

151313

Segment PBT (INR Cr)

716383

Revenue growth year on year (%)

-11.28.027.6

Contribution to total revenue (%)

100100100

Group Entities

EntityCountryOwnershipFunction

AVT Natural Products Ltd (parent)

India

Listed

Manufacturing, R&D, farmer network, export sales

AVT Natural Europe Ltd (formerly AVT Tea Services Ltd)

United Kingdom

100%

Marketing arm for decaffeinated and instant tea; European sales. FY2020: sales ₹59 crore, PAT ₹1.15 crore

AVT Natural North America Inc.

USA

100% (through AVT Natural Europe)

Sales and marketing of value-added teas, animal nutrition and natural extracts in North America

AVT Tea Services North America LLC

USA

—

US tea services/marketing

AVT Natural S.A. de C.V.

Mexico

100%

Animal-nutrition products for Latin America. FY2020: sales ₹2.17 crore, loss ₹3.33 crore

AVT Natural FZCO

Dubai, UAE

100%

Middle East / Africa trading and marketing hub (scope not detailed)

Segment Revenue

Metric (INR Cr, FY2026)StandaloneConsolidatedSubsidiaries (derived)

Revenue from operations

683.8713.229.4

Profit after tax

53.964.810.9

Income Statement and Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025FY2026

Revenue from operations (INR Cr)

559582517559713

Revenue growth (%)

15.34.1-11.28.027.6

Cost of revenue (INR Cr, StockAnalysis)

270.4244.8234.2259.3347.0

Gross profit (INR Cr, StockAnalysis)

289.0337.4283.1299.6366.2

EBITDA / operating profit (INR Cr, Screener)

106121797390

Depreciation (INR Cr)

1413141411

Operating income / EBIT before other income (INR Cr, StockAnalysis)

91.3107.665.559.378.2

Other income (INR Cr)

102131314

Interest expense (INR Cr, Screener)

55799

Pre-tax income (INR Cr)

97105716383

Effective tax rate (%)

2526252422

Net income (INR Cr)

72.977.453.348.264.8

EPS basic (INR)

4.785.083.503.174.26

EPS diluted (INR)

4.785.083.503.174.26

Dividend payout (%)

2120232219

DPS (₹, derived = payout × EPS; FY2026 reported)

1.001.020.810.700.80

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025FY2026

Gross margin (%)

51.758.054.753.651.4

EBITDA margin (%)

19.020.815.313.112.6

Operating (EBIT) margin (%)

16.318.512.710.611.0

Net margin (%)

13.013.310.38.69.1

Income Statement and Margin Analysis (%) (Quarterly)

MetricQ1FY26Q2FY26Q3FY26Q4FY26Q1FY27

Revenue from operations (INR Cr)

132.4160194226241.2

EBITDA (INR Cr)

1615233639.9

OPM (%)

129121616.6

PBT (INR Cr)

14.8515.7521.6430.4139.05

PAT (INR Cr)

12.1213.2917.3722.0231.10

EPS (INR)

0.800.871.141.452.04

Balance Sheet and Per-Share Data

MetricFY2022FY2023FY2024FY2025FY2026

Total assets (INR Cr)

449522598747846

Cash and equivalents (INR Cr, StockAnalysis)

14.320.125.833.630.9

Cash + short-term investments incl. liquid funds (INR Cr)

42.678.6153.5170.0147.2

Investments on balance sheet (INR Cr, Screener)

2858127136116

Trade receivables (INR Cr)

102.1121.4110.0156.4240.4

Inventory (INR Cr)

183.3212.0221.1293.7320.6

Total current assets (INR Cr)

362.3440.6510.6663.0756.7

Net fixed assets (INR Cr)

8278827281

Total borrowings (INR Cr)

253743113114

Net debt (INR Cr; negative = net cash, StockAnalysis)

-17.4-41.6-110.9-57.3-33.6

Share capital (INR Cr)

15.215.215.215.215.2

Reserves (INR Cr)

354415454491544

Shareholders' equity (INR Cr)

369430469506559

Book value per share (₹, derived)

24.228.330.833.236.7

Other liabilities (INR Cr)

555586128173

Net working capital (INR Cr, derived = current assets – borrowings – other liabilities, approximate)

282349382422470

Cash Flow and Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025FY2026

Operating cash flow (INR Cr)

74.451.298.5-32.512.0

Capex (INR Cr, derived = OCF – FCF, StockAnalysis)

8.08.012.59.223.4

Free cash flow (INR Cr)

66.443.286.1-41.7-11.4

Investing cash flow (INR Cr)

-28.9-36.8-73.0-9.41.3

Financing cash flow (INR Cr)

-45.0-8.5-20.250.0-16.0

CFO / EBITDA (%, Screener, pre-tax basis)

9564149-2533

Cash interest paid (INR Cr)

4.25.16.89.29.2

Cash taxes paid (INR Cr)

26.126.519.914.118.0

Share buybacks (INR Cr)

00000

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2022FY2023FY2024FY2025FY2026

ROE (%, derived on average equity)

21.519.411.99.912.2

ROA (%, derived on average assets)

16.715.99.57.28.1

ROCE (%, Screener)

2725161314

Current ratio (x, derived approximation)

4.54.84.02.82.6

Debt / equity (x)

0.070.090.090.220.20

Net debt / EBITDA (x; negative = net cash)

-0.16-0.34-1.40-0.78-0.37

Interest coverage (x, EBITDA / interest, derived)

21.224.211.38.110.0

Asset turnover (x, revenue / average assets)

1.281.200.920.830.90

Debtor days

677678102123

Inventory days

263342365431348

Payable days

454497146143

Cash conversion cycle (days)

284373346388327

Working-capital days

163177172171167

Revenue by Region (%)

MetricFY2020FY2025

Exports (% of standalone revenue)

9593

Domestic India (% of revenue)

57

United States (% of revenue, ICRA, approximate)

—45

Valuation Snapshot

MetricValueDate / source

Last close (NSE)

₹99.70

19 Oct 2026 (Screener)

Market capitalisation

₹1,519 crore

19 Oct 2026

52-week high / low

₹108 / ₹53.3

Screener

All-time high / low

₹135.70 / ₹4.89

ICICI Direct

1-year price change

+46%

Screener

3-year price CAGR

3%

Screener

5-year price CAGR

3%

Screener

10-year price CAGR

10%

Screener

Shareholders

45,138

Sep 2026

Share Price

MetricMar-2025Dec-2025Mar-2026Jul-2026Oct-2026

Share price (₹, approximate)

70685970100

Valuation Multiples

MultipleAVTBasis

P/E (TTM)

18.1x

Price ₹99.7 / TTM EPS ₹5.50

P/B

2.71x

Book value ₹36.7 (Mar 2026)

EV/EBITDA (TTM, derived)

about 13.1x

EV about ₹1,485 crore (market cap ₹1,519 crore less net cash ₹34 crore) / TTM EBITDA ₹113.6 crore

EV/Sales (TTM, derived)

about 1.8x

TTM revenue ₹822 crore

Dividend yield

0.80%

DPS ₹0.80

Sector / industry P/E

about 35–47x

Univest and Aaj Tak aggregators (FMCG classification). Not a like-for-like peer set

Returns & Leverage Ratios (%)

MetricFY2022FY2023FY2024FY2025FY2026

DPS (₹; FY2026 reported, earlier years derived from payout)

1.001.020.810.700.80

Payout ratio (%)

2120232219

Long-term by Date

DateLong-termShort-termRated amount (INR Cr)

7 Jan 2019

A (Stable)

A1

about 43

7 Jan 2020

A (Stable)

A1

about 99

11 Jan 2021

A+ (Stable) — upgraded

A1

—

31 Mar 2022

A+ (Stable)

A1+ — upgraded

—

12 Jun 2023

A+ (Stable)

A1+

98.88

30 Sep 2024

A+ (Stable)

A1+

98.88

22 Dec 2025

A+ (Stable)

A1+

114.48

Analyst Conclusions

Management guidance and consensus

  • No quantitative guidance is published and there is no sell-side consensus.

  • ICRA's Dec 2025 view expected stable performance and no material OPM improvement in the near to medium term, with capex of ₹15–20 crore a year. That margin view has since been exceeded: OPM was about 16–17% in Q4 FY2026 and Q1 FY2027.

Run-rate arithmetic (not a forecast): annualising Q1 FY2027 gives revenue of about ₹965 crore and PAT of about ₹124 crore. Seasonality makes simple annualisation unreliable. Q1 has historically been the weakest quarter, but Q1 FY2027 may include some pre-buying.

Bull case

  1. Operating leverage is real and visible. Revenue grew about 82% while EBITDA grew about 151% in Q1 FY2027, on a fixed-asset base of only about ₹81 crore. If revenue holds above ₹200 crore a quarter, ROCE can move toward ICRA's 20% upgrade threshold.

  2. Structural demand tailwinds in natural colours (US synthetic-dye phase-down), lutein (ageing populations) and RTD tea. Tariff relief on beverages from November 2025 adds to these.

  3. Valuation still undemanding. About 18x TTM P/E and about 13x EV/EBITDA for an A+-rated, net-cash company with a contracted offtake partner. Negligible institutional ownership leaves room for discovery if disclosure improves under a professional CEO.

Bear case

  1. Cash does not follow profit. Free cash flow was negative in FY2025 and FY2026 even as PAT rose. Debtor days rose to 123 and the cash conversion cycle exceeds 300 days. Reported earnings growth may be partly financed by customer credit.

  2. Concentration risk is binary. With the top five customers above 80% of revenue and the US at about 45%, losing or repricing a single contract — Kemin in particular — or a fresh US tariff could reverse the recovery. Chinese marigold pricing remains a structural cap.

  3. Cyclicality and base effects. Q1 FY2027 was compared against a weak base, and FY2024 showed that a poor crop season can cut revenue by double digits. The stock's 46% one-year rise, with repeated exchange volume enquiries, already prices in a good deal of the improvement.

Catalysts and monitorables (next 12 months)

ItemExpected timingWhat to watch
Q2 FY2027 resultsAbout mid-November 2026 (trading window closed 25 Sep)Whether revenue stays above ₹200 crore and OPM above 15%; receivables trend
H1 FY2027 balance sheetWith Q2 resultsOperating cash flow, inventory and debtor days
Marigold crop season (Kharif / Rabi 2026–27)Q3–Q4 FY2027Flower availability and procurement cost
US trade policyOngoingTariffs on non-beverage botanicals and colours
INR/USDOngoingRupee appreciation risk to margins
ICRA surveillanceAbout Dec 2026Possible positive outlook or upgrade if ROCE above 20%
CEO strategy articulationFY2027First investor communication, new markets, capex plans
Q4 FY2027 / FY2027 resultsMay 2027Full-year cash conversion; dividend step-up

Analyst verdict

AVT Natural Products enters late 2026 at its strongest operating point in its 40-year history. Quarterly revenue is above ₹240 crore, margins have recovered to about 16–17%, and TTM PAT is about ₹84 crore. Leadership has also changed: a professional chief executive now leads the company, with a five-year mandate and a background in multinational P&L and cash management. The franchise underneath is genuine. It rests on decades of marigold contract farming, an exclusive offtake with Kemin, a three-leg product portfolio that has broadened beyond marigold, and an A+-rated, net-cash balance sheet. At about 18x trailing earnings and about 13x EV/EBITDA, the market does not yet value AVT as a natural-ingredients compounder.

The case for a durable re-rating, however, depends on a variable the income statement does not show: cash conversion.

  • Over five years the company converted under half of its EBITDA into operating cash flow.

  • In FY2026, its best year, free cash flow was negative because receivables grew by about ₹84 crore.

  • Customer concentration (top five customers above 80%) and US exposure (about 45%) mean the recent revenue surge rests on a small number of buying decisions. The Q1 FY2027 growth rate is unlikely to be repeated once the base normalises.

Our synthesis is that AVT has moved from a value trap (FY2023–FY2025: shrinking returns, flat stock) to an earnings-recovery story with an unproven cash leg. The three things that would confirm a structural, rather than cyclical, improvement are:

  1. Positive free cash flow in H1 FY2027.

  2. Debtor days back below 100.

  3. Margins held above 15% through a full crop cycle.

If all three are met, an ICRA upgrade and wider institutional interest become plausible. If receivables and inventory keep absorbing the profit, the stock's 2026 rally will look like another momentum episode of the kind seen in 2021–2023.

Stance: Constructive on fundamentals. Cautious on near-term entry after a 46% rally. The H1 FY2027 cash-flow statement is the decisive monitorable.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameTitleTenureBackground

K. Nandakumar

Chief Executive Officer; designated Manager & CEO (KMP) for five years from 28 May 2026

CEO since 1 Sep 2025

30+ years across Philips, GE, 3M, Honeywell and TVS Rubber (most recently CEO, TVS Rubber). Focus on new markets, business models, P&L and cash-flow management. Age and education not disclosed in sources reviewed

M.N. Satheesh Kumar

Manager (Key Managerial Personnel)

28 May 2025 – 27 May 2026 (one-year term approved at 39th AGM); succeeded by the CEO as Manager

Long-serving executive.

P. Mahadevan

Company Secretary & Compliance Officer

Current

Signs exchange filings (e.g. Reg. 74(5) certificate, Apr 2026)

CFO

Chief Financial Officer

——

Board of Directors

NameRoleNotes

Ajit Thomas

Chairman (promoter); Non-Executive

Chairman of the A.V. Thomas Group; holds 1.00% directly.

Rahul Thomas (DIN 09762551)

Non-Executive Director (promoter family)

Appointed 12 Jun 2024; MBA, degree in Economics; retired by rotation and re-appointed at 40th AGM (17 Aug 2026)

Siddharth Thomas

Non-Executive Director (promoter family)

Additional Director from 9 Jun 2026; regularised at 40th AGM

Kavitha Vijay

Independent Director

Re-appointed for a second five-year term from 23 Sep 2025

A.D. Bopana

Former Independent Director

Retired 25 Aug 2025; committees reconstituted 26 Aug 2025

Other independent directors

Independent

—

Major Shareholders

HolderShares%

Neelamalai Agro Industries Ltd (promoter)

60,913,60040.00

Other promoter-group bodies corporate (combined)

about 51.5 million

about 33.85

Ajit Thomas (promoter, individual)

1,522,8401.00

Other promoter individuals / HUF (2 holders)

233,0000.15

Total promoter and promoter group (6 holders)

114,212,975

75.00

Investor Education & Protection Fund

—

about 1.17

Vistra ITCL (India) Ltd (largest named public holder)

—

about 1.01

Foreign portfolio investors (4 FIIs)

—

0.03 (0.04 Sep 2026)

Domestic institutions (incl. mutual funds: nil)

—0.02

Individuals and other public

—

about 22.8

Total public (52,201 holders at Mar 2026; 45,138 at Sep 2026)

38,071,025

25.00

Competitive Landscape

Competitors by Segment

CategoryCompetitorHQPositioning vs AVT

Marigold / lutein

Chinese marigold-extract producers, e.g. Chenguang Biotech Group

China

Largest global capacity in plant extracts; aggressive pricing, described by AVT's management as subsidy-assisted. The main threat to marigold margins

Marigold / lutein

Synthite Industries (private)

India (Kerala)

World's largest spice-oleoresin maker; also in marigold. Much larger scale

Marigold / lutein, spice

Plant Lipids (private)

India (Kerala)

Direct spice-oleoresin competitor

Marigold / lutein, nutraceutical

OmniActive Health Technologies (private)

India

Branded lutein (Lutemax); higher value-add

Marigold / lutein, nutraceutical

DSM-Firmenich, BASF

Netherlands/Switzerland, Germany

Synthetic or formulated lutein / carotenoids

Spice oleoresins

Mane Kancor (Mane group)

India / France

Spice extracts, flavours

Spice oleoresins

Akay Natural Ingredients (private)

India

Spice extracts, curcumin

Spice oleoresins

Givaudan (Naturex division)

Switzerland

Global natural extracts leader

Natural colours

Oterra; Sensient Technologies (Colours group)

Denmark; USA

Global natural-colour formulators that compete for and buy oleoresins

Instant / decaf tea

Finlays (Swire group)

UK

Global leader in tea extracts and soluble tea

Instant / decaf tea

Tata Consumer Products (instant tea operations)

India

Integrated tea major with extraction capacity

Instant / decaf tea

Martin Bauer Group (private)

Germany

Botanical and tea extracts

Botanical animal nutrition

Delacon (now part of Cargill), Phytobiotics (private), Natural Remedies (private)

Austria/USA; Germany; India

Phytogenic feed additives

Botanical animal nutrition

Kemin (feed division)

USA

Kemin is both customer and potential competitor

Peer Comparison FY2026

CompanyLatest FY revenueRevenue growthEBITDA marginComment

AVT Natural Products (FY2026, INR Cr)

713+27.6%

12.6% (TTM about 13.8%)

Verified

Sensient Technologies (2024, USD Mn, approximate)

about 1,560

low single-digit

—

Colours segment is a direct comparable for natural colours

Givaudan (2024, CHF Mn, approximate)

about 7,400

high single-digit

—

Taste & Wellbeing includes Naturex extracts

Tata Consumer Products (FY2025, INR Cr, approximate)

about 17,600

——

Instant-tea operations are a small part

Recent Developments

There were no layoffs, litigation or regulatory enforcement actions in this period beyond the minor exchange fines noted.

Company Snapshot

$82.3M

Revenue

320

Employees

1986

Founded

Chennai, India

Headquarters

SWOT Analysis

Strengths

  • Net-cash, conservatively financed balance sheet: Net cash ₹33.6 crore (FY2026); debt/equity 0.20x; ICRA A+ (Stable) / A1+ (Dec 2025)
  • Contracted offtake for the largest category: Exclusive long-term marigold-oleoresin supply agreement with Kemin Industries (ICRA, Dec 2025)
  • Backward integration in marigold: About 30,000 farmers, about 35,000 acres, about 100,000 MT of flowers a year (company release, 2020)
  • Diversified three-leg portfolio: Marigold under 40%, spice about 25%, beverages about 30% of FY2025 revenue (ICRA)
  • Demonstrated operating leverage in upturns: Q1 FY2027 revenue +82% produced EBITDA +151% and PAT +157% (DSIJ)
  • Consistent dividend payer: Payout of 19–29% every year from FY2015 to FY2026; FY2026 DPS ₹0.80
  • Stable promoter commitment: Promoter holding steady at 75.00% for 18+ quarters, with zero pledge

Weaknesses

  • Extreme customer concentration: Top five customers more than 80% of revenue (ICRA, Dec 2025)
  • Geographic concentration: US about 45% of FY2025 sales; exports about 93% (ICRA)
  • Poor cash conversion: Negative free cash flow in FY2025 (–₹41.7 crore) and FY2026 (–₹11.4 crore); cumulative five-year OCF/EBITDA about 43%
  • Very long working-capital cycle: Cash conversion cycle 327–388 days in FY2023–FY2026; debtor days up from 78 to 123 (FY2024 → FY2026)
  • Slow long-run growth until FY2026: Five-year sales CAGR about 8%; three-year profit CAGR –5% (Screener, to FY2026)
  • Margin compression from mix: EBITDA margin fell from about 21% (FY2023) to 12.6% (FY2026); gross margin fell from 58.0% to 51.4%
  • Limited disclosure and investor engagement: No earnings calls or investor presentations; negligible institutional ownership (FII 0.04%, mutual funds nil)

Opportunities

  • Natural-colour substitution in the US: Paprika, capsicum and marigold colour portfolio; US is about 45% of sales
  • Animal-nutrition scale-up: Segment growth more than 60% in FY2025 (ICRA); US, Mexico and UAE subsidiaries in place
  • Tea tariff relief: US withdrew the beverage tariff in November 2025 (ICRA)
  • Professional CEO driving new markets and business models: K. Nandakumar's mandate and five-year term (May 2026)
  • Working-capital release could unlock cash: Every 30-day cut in the cash conversion cycle frees roughly ₹60 crore at FY2026 revenue (derived)
  • Rating upgrade path: ICRA upgrade trigger is sustained ROCE above 20%. TTM ROE of about 15.5% after Q1 FY2027 moves toward it

Threats

  • Chinese marigold-oleoresin price competition: Cited explicitly in annual-report MD&A as subsidy-aided low pricing
  • Agro-climatic risk: A poor marigold season contributed to the FY2024 revenue decline (–11%)
  • Currency risk: Exports about 93%; only about 50% of receivables hedged (ICRA)
  • Trade-policy risk: US reciprocal tariffs constrained FY2026 growth (ICRA)
  • Loss or renegotiation of a key customer contract: Top five customers more than 80% of revenue; Kemin exclusivity cuts both ways
  • Environmental compliance costs: ICRA flags solvent waste and agri-waste norms as a potential capex need
  • Valuation momentum risk: Stock up about 46% in one year, with repeated exchange volume enquiries (Sep and Oct 2026)

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
28 May 2025M.N. Satheesh Kumar appointed Manager (KMP) for one yearInterim leadership arrangement
29 May 2025Q4 FY2025 results: total income ₹129.5 crore (–27% QoQ); PAT ₹10.96 crore (–22.5% YoY)Trough quarter
FY2025 closeFY2025: revenue ₹559 crore (+8%), PAT ₹48.2 crore (–9.5%), operating cash flow –₹32 croreWeakest profit year in five
13–14 Aug 2025Q1 FY2026: total income ₹136.3 crore (+24.6% YoY), PAT ₹12.1 crore (+103% YoY)First sign of recovery
13–14 Aug 2025Board appoints K. Nandakumar as CEO from 1 Sep 2025; Kavitha Vijay re-appointed Independent DirectorProfessionalisation of management
13 Aug 202539th AGMRoutine approvals; Manager appointment
25–26 Aug 2025Independent Director A.D. Bopana retires; committees reconstitutedBoard transition
1 Sep 2025CEO assumes officeLeadership change
2025 (H1 FY2026)US reciprocal tariffs weigh on export demand (ICRA)Headwind
3 Nov 2025Exchange seeks volume clarification; board meeting fixed for 13 Nov 2025Market attention
13 Nov 2025Q2 FY2026: total income ₹165.6 crore, PAT ₹13.3 crore; limited review by Suri & Co.H1 revenue +29% YoY
Nov 2025US withdraws tariff on beverages (incl. tea)Tailwind for instant/decaf tea
2 Dec 2025Stock trades near ₹68; market cap about ₹1,037 crore—
22 Dec 2025ICRA reaffirms A+ (Stable) / A1+; limits enhanced to ₹114.48 croreCredit stability confirmed
11–12 Feb 2026Q3 FY2026: total income ₹197.4 crore (+11.5% YoY), PAT ₹17.4 crore (–19.6% YoY); 9M standalone revenue ₹467.4 crore; interim dividend ₹0.35 (record date 19 Feb 2026)Revenue up, margin still below Q3 FY2025
2–20 Mar 2026Stock falls to about ₹59 (market cap about ₹937 crore) amid broader market weaknessLow point of the year
9 Apr 2026Reg. 74(5) compliance certificate filed (Q4 FY2026)Routine
20 May 2026Board meeting intimation for FY2026 results—
28 May 2026FY2026 results: revenue ₹713 crore (+28%), PAT ₹64.8 crore (+34%); Q4 PAT ₹22.0 crore (+53% YoY); final dividend ₹0.45; CEO appointed for five yearsRecord revenue
29 May 2026FY2026 secretarial compliance report filed; earlier minor exchange fines (₹25,960) notedGovernance hygiene
9 Jun 2026Siddharth Thomas appointed Additional DirectorNext-generation promoter on board
26 Jul 202640th AGM notice; remote e-voting from 14 Aug 2026; scrutiniser V Suresh Associates—
14 Aug 2026Q1 FY2027: revenue ₹241.2 crore (+82%), EBITDA about ₹39.9 crore (+151%), PAT ₹31.1 crore (+157%), EPS ₹2.04; stock +12.9%Record quarter; inflection
17 Aug 202640th AGM: approves CEO tenure and remuneration, directors—
28 Aug 2026Stock at ₹85.8; 52-week high ₹92.8Re-rating
4 Sep 2026Stock at ₹91.6 (+29.6% in one month)Momentum
23 Sep 2026Exchange volume clarification; company denies undisclosed information; stock about ₹97Speculative interest
25 Sep 2026Trading window closed ahead of Q2 FY2027 resultsResults pending
9 Oct 2026Reg. 74(5) certificate for quarter to 30 Sep 2026; Sep 2026 shareholding shows promoter holding at 75.00%Routine
12 Oct 2026Second volume clarification; no price-sensitive event—
19 Oct 2026Stock closes at ₹99.70; market cap about ₹1,519 crore; 52-week high ₹108Near all-time-high territory of the past five years. The all-time high is ₹135.70

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

4 charts
Income Statement: Revenue & Gross Profit: Revenue from operations rose from INR 5,590 Mn in FY2022 to INR 7,130 Mn in FY2026.
AVT Natural Products Limited — Income Statement: Revenue & Gross Profit
Series (INR Mn)FY2022FY2023FY2024FY2025FY2026
Revenue from operations5,5905,8205,1705,5907,130
Cost of revenue2,7042,4482,3422,5933,470
Gross profit2,8903,3742,8312,9963,662

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. NSE integrated filing (Ind AS, iXBRL), FY2026 results approved 28 May 2026 — nsearchives.nseindia.com
  2. ICRA rating rationales
  3. 22 Dec 2025 (full text reviewed)
  4. 30 Sep 2024
  5. 12 Jun 2023
  6. 31 Mar 2022
  7. 11 Jan 2021
  8. 7 Jan 2020
  9. 7 Jan 2019
  10. All at icra.in
  11. Shareholding pattern, 31 Mar 2026 (via Emkay Global and Upstox, from BSE/NSE)
  12. Promoter Reg. 30 SAST disclosures (NSE archives, 2020–2021)
  13. DSIJ — Q1 FY2027 results (14 Aug 2026)
  14. Kotak Neo — Q4 FY2025, Q1 FY2026, Q3 FY2026 and Q4 FY2026 result summaries
  15. Univest — Q1 FY2027 results; sector comparison (23 Sep 2026)
  16. StockGro (SEBI RA commentary)
  17. ScanX — CEO appointment; FY2026 results; AGM notice; board committee changes
  18. Screener.in — consolidated P&L, balance sheet, cash flow, ratios, shareholding and announcements; price as of 19 Oct 2026
  19. StockAnalysis — income statement, balance sheet, cash flow (₹ million)
  20. Value Research Online — TTM figures, peer comparison (5 Oct 2026)
  21. Marketsmojo (Motilal Oswal) — shareholding and annual figures
  22. Fyers — FY2026 profit and loss
  23. TipRanks — statistics and ratios
  24. Upstox, Choice India, ICICI Direct, IIFL, Kotak Securities, Anand Rathi, blinkx — price history
  25. Morningstar Australia — company profile (address, employees)
  26. Wright Research — company profile and price
  27. Outlook Business — "Will AVT Natural Products be back in favour?"
  28. IIFL — management discussion extract
  29. Engormix — Michael Putnam appointment (24 Mar 2020)
  30. Invest Yadnya and TradingView — subsidiary descriptions

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.